What Zydus Pharmaceuticals does

Zydus Pharmaceuticals (USA) Inc. is a Pennington, New Jersey-based generic pharmaceutical company and the wholly-owned US drug division of Zydus Lifesciences Limited (formerly Cadila Healthcare Limited), India's fourth largest pharmaceutical company. Founded in 2003 and operating commercially since its first product launch in 2005, the company markets more than 170 FDA-approved generic products across over 500 SKUs spanning tablets, capsules, injectables, transdermals, creams, and ointments, and has been ranked the 5th largest unbranded generic corporation in the United States by dispensed prescriptions (IQVIA, NPA Audit, MAT March 2026). Its regulatory footprint includes 280+ approved ANDAs, 145+ drug master files, and 75+ ANDAs pending at USFDA.

The product mix is anchored in complex generics (modified release solid orals, transdermals, injectables, oral suspensions) and is being progressively augmented with branded 505(b)(2) products including Beizray (docetaxel injection), JAYTHARI (deflazacort tablets), and Zituvio (sitagliptin tablets), as well as biosimilars such as FYB206 (pembrolizumab). Manufacturing is supported by 8 FDA-approved finished dosage sites and 2 FDA-approved API plants across India and the United States; the parent operates more than 30 manufacturing plants worldwide producing over 28 billion pills annually.

Zydus generates revenue by selling FDA-approved generic and branded pharmaceuticals through licensed retail and mail-order pharmacies, healthcare providers, and wholesale distribution channels across the US. The company does not sell directly to patients and does not control downstream pharmacy or PBM pricing. Recent strategic moves—an exclusive 2025 biosimilar licensing agreement with Formycon for FYB206 and a 2026 acquisition of two Agenus biologics manufacturing facilities through subsidiary Zylidac Bio LLC—indicate an explicit pivot from pure generics into higher-value biosimilars and in-house biologics manufacturing, while the parent group's 55-country footprint underwrites global distribution optionality.

Name

Zydus Pharmaceuticals

Legal name

Zydus Pharmaceuticals (USA) Inc.

Website

https://zydususa.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Zydus Pharmaceuticals (USA) Inc. is the US generic drug division of India-based Zydus Lifesciences, marketing over 170 FDA-approved generic products plus branded 505(b)(2) products to pharmacies and healthcare providers nationwide. It ranks as the 5th largest unbranded generic corporation in the US by dispensed prescriptions.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Generic & Private-Label Veterinary Pharmaceuticals (HLAMAEAM), Generic Hospital & Institutional Products (HLAIABAL), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Generic pharmaceutical manufacturing
• FDA-approved medications
• Complex generic formulations
• Branded pharmaceutical products
• Animal health products

Headquarters

HQ city

Pennington

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Sales: Revenue generated through sale of FDA-approved generic medications to pharmacies and healthcare providers across the US market. Products include tablets, capsules, injectables, creams, ointments, and other dosage forms distributed through licensed pharmacies.
2. Branded Pharmaceutical Products: Sale of branded FDA-approved products including Beizray (docetaxel) injection and JAYTHARI (deflazacort) tablets, representing expansion beyond commoditized generics into innovative branded treatments.
3. Biosimilar Licensing: Revenue from exclusive licensing supply agreements for biosimilars, such as the agreement with Formycon for Keytruda (pembrolizumab) biosimilar (FYB206) in the US and Canada.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Zydus Pharmaceuticals (USA) Inc. manufactures and distributes FDA-approved generic and branded pharmaceutical products in the US market. The core offering consists of over 170 FDA-approved generic medications (with 500+ SKUs) including tablets, capsules, creams, ointments, injectables, transdermals, and other dosage forms, supplemented by a growing portfolio of branded 505(b)(2) products such as Beizray (docetaxel) injection, JAYTHARI (deflazacort) tablets, and Zituvio (sitagliptin) tablets. The company also operates a biosimilar licensing business and an animal health subsidiary (ZyVet Animal Health).

Product overview

Zydus Pharmaceuticals (USA) Inc. is a leading generic pharmaceutical company and the US generic drug division of Zydus Lifesciences. The company operates as a single unified product portfolio centered on FDA-approved generic medications, supplemented by a growing selection of branded 505(b)(2) products. The core offering consists of over 170 FDA-approved generic products (with over 500 SKUs) including tablets, capsules, creams, ointments, injectables, and transdermal systems across various therapeutic categories. The branded portfolio includes Beizray (docetaxel) injection, JAYTHARI (deflazacort) tablets, and Zituvio (sitagliptin) tablets. Notable products include mesalamine DR tablets (with CGT exclusivity), methylene blue injection, nelarabine injection, and rivastigmine transdermal patches. The company offers product directories (generic and branded), medication guides, and partner resources through its website, with additional services including the ZyVet Animal Health subsidiary. The portfolio is supported by manufacturing facilities in India and the US, with capabilities across formulations, APIs, and biologics.

Differentiator

Problem solved

Functional benefit

Brands

• Beizray: FDA-approved docetaxel injection for intravenous use - first and only FDA approved Docetaxel + Albumin injection. Zydus' first 505(b)(2) oncology product commercialized in 2025.
• Zituvio
• Jaythari

Products and services

• Generic Pharmaceutical Products Over 170 FDA-approved generic medications across a wide variety of therapeutic categories including tablets, capsules, creams, ointments, injectables, and transdermal systems. Products include generic versions of cardiovascular medications, oncology drugs, and various therapeutic treatments, sold through licensed retail and mail-order pharmacies across the US.
• Beizray (docetaxel) injection FDA-approved docetaxel injection for intravenous use, marketed as Zydus's first 505(b)(2) branded oncology product. It is the first and only FDA-approved Docetaxel + Albumin injection, supplied as a kit or individually as single dose vials, for healthcare providers treating oncology patients.
• JAYTHARI (deflazacort) tablets FDA-approved deflazacort tablets branded product, available for ordering through a dedicated product website with copay information. Targeted at patients requiring deflazacort treatment.
• Zituvio (sitagliptin) tablets Sitagliptin tablets marketed as Zydus (USA)'s first 505(b)(2) branded product, commercialized in 2023 for the treatment of type 2 diabetes.
• Mesalamine DR tablets Delayed-release mesalamine tablets for inflammatory bowel disease, launched in 800mg (2016) and 1.2gm (2017) strengths with 180-day exclusivity periods.
• Methylene blue injection First AP-rated generic of methylene blue injection, launched in 2023, used for methemoglobinemia and as a diagnostic dye.
• Nelarabine injection Nelarabine injection launched in 2021 as Zydus (USA)'s first product with Competitive Generic Therapy (CGT) exclusivity, used for T-cell acute lymphoblastic leukemia treatment.
• Rivastigmine Transdermal System First transdermal product from Zydus (USA) to secure USFDA approval in 2019, used in the treatment of Alzheimer's disease.
• Atenolol tablets First product launched by Zydus (USA) in August 2005; a beta-blocker tablet used to treat cardiovascular conditions such as hypertension and angina.
• ZyVet Animal Health Animal health subsidiary of Zydus (USA), incorporated in New Jersey in April 2019, offering animal health pharmaceutical products in the US market.
• FYB206 Keytruda (pembrolizumab) Biosimilar Pembrolizumab biosimilar developed by Formycon, for which Zydus holds the exclusive licensing supply agreement for the US and Canada market (signed 2025). Represents Zydus's strategic expansion into the biosimilar market and complex biologics.

Quantifiable outcome

• In 2017, $265.1 billion was saved through the use of generics in the US (AAM)

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Agenus Inc.coreStrategic or Co-development Partner · 1 January 2026Zydus (USA) acquired two biologics manufacturing facilities from Agenus Inc. through its subsidiary Zylidac Bio LLC. This acquisition strengthens Zydus's biologics manufacturing capabilities and represents a significant expansion into biologics manufacturing.
• FormyconcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2025Exclusive licensing supply agreement with Formycon for FYB206, a Keytruda (pembrolizumab) biosimilar, in the US and Canada. This partnership represents Zydus's strategic expansion into the biosimilar market and complex biologics.
• Agenus Inc.minorStrategic or Co-development Partner · 1 January 2025CFIUS review pending for transactions involving manufacturing assets, a minority equity position, and commercial rights in India and Sri Lanka with Agenus Inc.

Scale indicators14 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Apotex: Canadian-based generic pharmaceutical manufacturer with a substantial US presence across oral solids, injectables, and APIs. Competes with Zydus in the same US generic pharmacy channels.
• Teva Pharmaceutical Industries: Largest US generic manufacturer by prescriptions and a global leader in both small-molecule generics and complex generics (sterile injectables, respiratory, CNS). Competes head-to-head with Zydus across Zydus's core US generic portfolio.
• Dr. Reddy's Laboratories: Indian-headquartered integrated pharma company with a large US generics business across oral solids, injectables, and biosimilars. Closely comparable to Zydus in product mix, scale, and India-manufacturing footprint.
• Glenmark Pharmaceuticals: India-headquartered generics and specialty pharma company with a US-focused generics business across oral solids, injectables, and dermatology. Comparable product mix and India-US operating model to Zydus.
• Amneal Pharmaceuticals: US-based generic and specialty pharma company with portfolio breadth across oral solids, injectables, and biosimilars (similar to Zydus's Affinity/AvKARE units). Competes with Zydus across US retail and institutional channels.
• Hikma Pharmaceuticals: Jordan-headquartered generics and injectables manufacturer with a sizable US business. Comparable to Zydus in oral generics, injectables, and emphasis on complex formulations for US customers.
• Aurobindo Pharma: India-headquartered generics manufacturer with a large US business spanning oral solids, injectables, and APIs. Directly comparable scale and product mix to Zydus Pharmaceuticals (USA).
• Sandoz (Novartis): Global generics and biosimilars leader that competes directly with Zydus in US small-molecule generics and increasingly in biosimilars, mirroring Zydus's complex-generics-plus-biosimilars strategy.
• Lupin Pharmaceuticals: Indian-headquartered global generics company with significant US sales in oral contraceptives, complex generics, and biosimilars — directly comparable to Zydus's US generic and emerging biosimilar footprint.

Broad incumbents

• Endo International: US-based specialty and generics pharma with significant sterile injectables and complex generics exposure. A broader incumbent in the same US generic and specialty channels where Zydus competes.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/zydus-pharmaceuticals-usa-inc-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zydus Pharmaceuticals